首页> 外文期刊>Amino acids >Radiolabeled new somatostatin analogs conjugated to DOMA chelator used as targeted tumor imaging agent: synthesis and radiobiological evaluation
【24h】

Radiolabeled new somatostatin analogs conjugated to DOMA chelator used as targeted tumor imaging agent: synthesis and radiobiological evaluation

机译:与DOMA螯合剂偶联的放射性标记的新生长抑素类似物用作靶向肿瘤显像剂:合成和放射生物学评估

获取原文
获取原文并翻译 | 示例
           

摘要

Several receptor-specific radiopeptides have been developed and effective in the diagnosis of malignant diseases. Among them, somatostatin receptor (SSTR) scintigraphy with In-111-DTPA-octreotide has become a tumor diagnostic radiopharmaceutical in nuclear medicine. However, it suffers some drawbacks concerning the imaging properties and elevated radiation burden of In-111. Here, we report the synthesis of radiolabeled two new octapeptides with improved uptake in SSTR2-positive tumors in comparison with Tc-99m-HYNIC-Tyr(3)-octreotide (HYNIC-TOC). Octapeptides were synthesized in high yield by Fmoc solid-phase synthesis and coupling the macrocyclic chelator DOMA(1,4,7-Tri-Boc-10-(carboxymethyl)-1,4,7,10-tetraazocyclododecane-1-yl-monoacetic acid) to these peptides for Tc-99m labeling. New peptides DOMA-Asn(3)-octreotate(DOMA-AATE) and DOMA-Pro(3)-octreotate(DOMA-PATE) were purified, characterized by RP-HPLC, MALDI-mass, H-1-NMR, C-13-NMR. Labeling was performed by SnCl2 method to get products with excellent radiochemical purity (97 %). Radiopeptides were found to be substantially stable under physiological condition for 24 h. Internalization and receptor-binding studies were determined in somatostatin receptor-expressing C6-glioma cell line and rat brain cortex membrane and the results compared with HYNIC-TOC as standard. The IC50 values of Tc-99m-DOMA-AATE(1.10 +/- A 0.48 nM) and Tc-99m-DOMA-PATE(1.76 +/- A 0.06 nM) showed high affinity binding for SSTR2 receptor and they internalized rapidly in C6 cells. Biodistribution and imaging studies were performed in C6 tumor-bearing rat under gamma camera showing significant uptake in kidney, urine and C6 tumor. Radiopeptides exhibited fast blood clearance and rapid elimination through the urinary systems. However, Tc-99m-DOMA-AATE exhibited the highest tumor to muscle and tumor to blood uptake ratios among three. These favorable characteristics validate Tc-99m-DOMA-AATE as a more promising Tc-99m-radiotracer than Tc-99m-DOMA-PATE, Tc-99m-HYNIC-TOC for SSTR2-positive tumor scintigraphy.
机译:已经开发了几种受体特异性放射性肽,它们在恶性疾病的诊断中是有效的。其中,用In-111-DTPA-奥曲肽进行生长抑素受体(SSTR)闪烁显像已成为核医学中的肿瘤诊断放射性药物。但是,它具有与In-111的成像特性和较高的辐射负荷有关的一些缺点。在这里,我们报告与Tc-99m-HYNIC-Tyr(3)-奥曲肽(HYNIC-TOC)相比,放射性标记的两个新八肽的合成具有改善的SSTR2阳性肿瘤摄取。通过Fmoc固相合成和偶联大环螯合剂DOMA(1,4,7-Tri-Boc-10-(羧甲基)-1,4,7,10-四偶氮环十二烷-1-基-单乙酸)高产合成八肽酸)对这些肽进行Tc-99m标记。纯化了新的肽DOMA-Asn(3)-奥曲肽(DOMA-AATE)和DOMA-Pro(3)-奥曲肽(DOMA-PATE),RP-HPLC,MALDI-mass,H-1-NMR,C- 13 -NMR。通过SnCl2方法进行标记,可得到具有优异放射化学纯度(97%)的产品。发现放射性肽在生理条件下24小时基本稳定。在表达生长抑素受体的C6-神经胶质瘤细胞系和大鼠大脑皮质膜中确定内在化和受体结合研究,并将结果与​​HYNIC-TOC进行比较。 Tc-99m-DOMA-AATE(1.10 +/- A 0.48 nM)和Tc-99m-DOMA-PATE(1.76 +/- A 0.06 nM)的IC50值显示出对SSTR2受体的高亲和力结合,并在C6中快速内在化细胞。在具有C6肿瘤的大鼠中,在伽马相机下进行了生物分布和成像研究,结果表明肾脏,尿液和C6肿瘤吸收显着。放射性肽表现出快速的血液清除和通过泌尿系统的快速清除。然而,Tc-99m-DOMA-AATE表现出最高的肿瘤与肌肉和肿瘤与血液吸收比,这是三者中最高的。这些有利的特征证明,对于SSTR2阳性肿瘤闪烁显像,Tc-99m-DOMA-AATE比Tc-99m-DOMA-PATE,Tc-99m-HYNIC-TOC更有望成为Tc-99m-放射性示踪剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号